Geneva, February 20, 2020 - Endeavour Vision led the Series B funding round for Boston-based IntelyCare, along with Kaiser Permanente Ventures and Generator Ventures, allowing the company to raise $45 million in new equity and debt financing. With aging populations and an increase in chronic diseases, more people need [...]
Endeavour Vision, Kaiser Permanente Ventures, and Generator Ventures Join Existing Investors in Round, Leveraging Gig Economics to Close Projected 1 Million Nurse Shortfall by 2030; Builds on Company’s Exceptional Momentum QUINCY, MA – February 20, 2020 – IntelyCare, a leading intelligent workforce management solution for post-acute facilities, today announced [...]
Seasoned Veteran Tom Griffin Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb. 4, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that Tom Griffin has joined Nuvaira as Chief Financial Officer. Tom Griffin has a 30-year track record of strong leadership guiding [...]
Zurich-Schlieren, Switzerland, December 27, 2019. Molecular Partners AG (SIX:MOLN), a clinical stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug Administration (FDA) for its novel therapeutic, MP0250, for the treatment of Multiple [...]
In June 2019, Bradley Paddock joined CeQur®, as Chief Executive Officer. We spoke to Bradley to hear about his first 6 months in the company and discuss the up-coming U.S. launch of its three-day insulin delivery device for type 2 diabetes. You probably had many career options after Kyphon [...]
Interview with Dennis Wahr, President and CEO, Nuvaira In 2019, Nuvaira was accepted into a unique program developed by the Haute Autorité de Santé (HAS, the French health technology assessment agency), the Forfait Innovation Program. We spoke to Nuvaira’s CEO Dennis Wahr to learn more. Can you summarise [...]
2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. - November 11, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today the full launch of the [...]
Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year Abicipar sustained vision gains in year two with quarterly injections compared to monthly ranibizumab Reductions in central retinal thickness were lower in [...]
V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension V-Wave’s two distinct FDA Breakthrough Device Designations illustrate the company’s dedication to innovation and improving outcomes for two debilitating diseases – Heart Failure and Pulmonary Arterial Hypertension CAESAREA, Israel, September 12, 2019 – V-Wave Ltd., [...]
The acceptance and authorisation are for Abicipar pegol in patients with neovascular (wet) age-related macular degeneration Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen Approvals in the United States and Europe are anticipated in 2020 DUBLIN, IRELAND – [...]